VYM dividend yield: 2.91%. MRK dividend yield: 3.25%. VYM tracks the FTSE High Dividend Yield Index, holding ~450 large-cap US companies with above-average dividend yields. With an ultra-low 0.06% expense ratio, it's one of the cheapest dividend ETFs available. Excellent core holding for long-term dividend growth investors seeking broad diversification and reliable income. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
VYM tracks the FTSE High Dividend Yield Index, holding ~450 large-cap US companies with above-average dividend yields. With an ultra-low 0.06% expense ratio, it's one of the cheapest dividend ETFs available. Excellent core holding for long-term dividend growth investors seeking broad diversification and reliable income.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
VYM currently offers a 2.91% yield (3.44/share/year) while MRK offers 3.25% (3.08/share/year). MRK provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in VYM vs MRK earn per year?
With $10,000 invested today: VYM pays approximately $291/year. MRK pays approximately $325/year. With DRIP reinvestment over 10 years, these grow to $785/year (VYM) and $950/year (MRK).
Does VYM or MRK pay monthly dividends?
VYM pays quarterly dividends. MRK pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this VYM vs MRK comparison by email
Save your analysis + get weekly dividend insights. Free forever.